Health Care & Life Sciences » Biotechnology | Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
264
210
203
329
1,079
1,174
Total Accounts Receivable
4
2
4
5
29
64
Inventories
-
-
-
13
84
125
Other Current Assets
3
35
17
27
37
62
Total Current Assets
271
248
225
373
1,229
1,426
Net Property, Plant & Equipment
15
39
37
38
43
97
Total Investments and Advances
1
-
1
1
11
33
Intangible Assets
5
6
7
8
14
12
Other Assets
-
3
4
4
11
75
Total Assets
292
295
274
424
1,308
1,642
ST Debt & Current Portion LT Debt
-
3
8
10
6
Accounts Payable
18
12
20
30
8
Income Tax Payable
-
-
-
-
1
Other Current Liabilities
18
22
34
36
73
Total Current Liabilities
36
37
62
75
88
Long-Term Debt
2
4
15
6
425
Other Liabilities
7
7
6
6
6
Total Liabilities
44
47
83
87
519
Common Equity (Total)
247
248
190
337
789
Total Shareholders' Equity
247
248
190
337
789
Total Equity
247
248
190
337
789
Liabilities & Shareholders' Equity
292
295
274
424
1,308

About Sarepta Therapeutics

View Profile
Address
215 First Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.sareptatherapeutics.com
Updated 07/08/2019
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.